Goss

Stock Market

Gossamer Bio’s stock falls 64% on findings for Phase 2 study for hypertension drug

December 6, 2022
Photo of Gossamer Bio’s stock falls 64% on findings for Phase 2 study for hypertension drug

[ad_1] Shares of Gossamer Bio Inc. GOSS, +2.99% plunged 64.5% in premarket trading on Tuesday after Wall Street analysts questioned…

Read More »
Back to top button
Close